GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.

Pharmaceutical

GV20 Therapeutics

Shirley Liu

Flavian D. Brown

Xihao Hu

Xingfeng Bao

Jie Chen

Karim Benhadji

Sherlock Hu

Ying Gong

Ted Xiao

The Leadership Team at GV20 Therapeutics is responsible for driving the strategic vision and operational execution of the company. This team, comprised of co-founders and key executives, oversees the integration of high-throughput functional genomics and AI technologies in drug discovery processes, fosters collaborations and partnerships, and guides the development of innovative immuno-oncology therapies to advance cancer treatment.

Leadership Team

Research and Development

Information Technology

Leadership Team

About

Team members

Other teams at GV20 Therapeutics

Research and Development

Information Technology